Price Chart

Profile

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
URL https://www.imux.com
Investor Relations URL https://ir.imux.com
HQ State/Province New York
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release May. 10, 2024 (est.)
Last Earnings Release Feb. 22, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
URL https://www.imux.com
Investor Relations URL https://ir.imux.com
HQ State/Province New York
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release May. 10, 2024 (est.)
Last Earnings Release Feb. 22, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A